Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape

Abstract excerpt

Autoimmune diseases remain a major cause of chronic morbidity despite substantial advances in targeted immunomodulatory therapies. In many autoantibody-mediated conditions, disease refractoriness and relapse are driven by long-lived plasma cells, which are largely resistant to conventional immunosuppression and upstream B cell-directed strategies. CD38, a surface molecule highly expressed on plasmablasts and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Calcium signaling and nucleotide metabolism
• Share to Chronic Lymphocytic Leukemia Research
• Share to Multiple Myeloma Research and Treatments